uploads/2018/04/thermometer-1539191_1280.jpg

Analysts’ Ratings for FibroGen and Its Peers in April 2018

By

Updated

Company overview

FibroGen (FGEN) is a biopharmaceutical company involved in the discovery and development of first-in-class therapeutics. Its most advanced product candidate is Roxadustat (or FG-4592). The drug is in Phase 3 of development for the treatment of anemia in chronic kidney disease.

The company has adopted a global approach to the development and commercialization of its product candidates. This approach includes its development and commercialization activities in China.

Article continues below advertisement

Analysts’ ratings

Of the seven analysts covering FibroGen in April 2018, five analysts have given the stock “strong buy” ratings, while two have given it “hold” ratings. The mean rating for the stock is 1.57, and its target price is $70.5.

Peers’ ratings

Of the ten analysts covering Acorda Therapeutics (ACOR) in April 2018, three have given the stock “buy” ratings, six have given it “hold” ratings, and one has given it a “sell” rating. The mean rating for the stock is 2.8, and its target price is $24.78.

Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten analysts have given the stock “buy” or higher ratings. Seven analysts have given Intercept “hold” ratings, while three have given it “sell” ratings. The mean rating for the stock is 2.5, and its target price is $110.91.

Of the six analysts covering Conatus Pharmaceuticals (CNAT) in April 2018, two analysts have given the stock “strong buy” ratings, while four have given it “buy” ratings. The mean rating for the stock is 1.67, and its target price is $15.83.

In the next part of the series, we’ll take a look at FibroGen’s research pipeline.

Advertisement

More From Market Realist